GO:0042359 vitamin D metabolic process: Endocrine Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042359 vitamin D metabolic process describes the chemical reactions and pathways involving vitamin D, including calciferol (ergocalciferol; vitamin D2) and cholecalciferol (calciol; vitamin D3).
• Vitamin D is a fat-soluble secosteroid derived from delta-5,7 steroids and plays a central role in calcium metabolism.
• The process includes absorption, transport, hepatic 25-hydroxylation, renal 1-alpha-hydroxylation, and catabolism, with vitamin D-binding protein as a key carrier.
• Key enzymes include CYP2R1, CYP27B1, CYP24A1, and CYP3A4, while the vitamin D receptor (VDR) mediates genomic effects.
• Dysregulation of vitamin D metabolism is linked to chronic kidney disease, vitamin D toxicity, and altered mineral homeostasis.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of genes in this pathway.
Description
Vitamin D metabolic process (GO:0042359) encompasses the chemical reactions and pathways involving vitamin D, a group of fat-soluble compounds derived from delta-5,7 steroids that are essential for calcium metabolism. The term includes specific forms such as calciferol (ergocalciferol; vitamin D2) and cholecalciferol (calciol; vitamin D3), as well as their metabolites. Understanding this process is fundamental for researchers in endocrinology, nutrition, and bone biology because vitamin D status influences skeletal health, immune function, and chronic disease risk. The pathway involves sequential enzymatic modifications, transport by vitamin D-binding protein, and receptor-mediated signaling. This article integrates authoritative QuickGO annotation with real PubMed literature to provide a research-grade overview of GO:0042359, its genes, regulation, disease relevance, and experimental methods.
vitamin D metabolic process At A Glance
| GO ID | GO:0042359 |
|---|---|
| GO term | vitamin D metabolic process |
| Ontology | biological_process |
| Synonym | calciferol metabolic process; cholecalciferol metabolic process; ergocalciferol metabolic process; vitamin D metabolism |
| Definition | The chemical reactions and pathways involving vitamin D, any of a group of related, fat-soluble compounds that are derived from delta-5,7 steroids and play a central role in calcium metabolism. |
| Major function | Production, activation, transport, and degradation of vitamin D compounds to regulate calcium and phosphate homeostasis. |
| Key forms | Vitamin D2 (ergocalciferol), vitamin D3 (cholecalciferol), 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D |
| Related diseases | Chronic kidney disease, vitamin D toxicity, disorders of mineral metabolism |
What Is GO:0042359?
GO:0042359 vitamin D metabolic process is defined as the chemical reactions and pathways involving vitamin D, any of a group of related, fat-soluble compounds that are derived from delta-5,7 steroids and play a central role in calcium metabolism. Specific forms of vitamin D include calciferol (ergocalciferol; vitamin D2) and cholecalciferol (calciol; vitamin D3). Synonyms include calciferol metabolic process, cholecalciferol metabolic process, ergocalciferol metabolic process, and vitamin D metabolism.
Why Is vitamin D metabolic process Important in Cell Biology?
Vitamin D metabolic process is critical because it governs the bioavailability and biological activity of a secosteroid hormone that regulates calcium and phosphate homeostasis, bone mineralization, and numerous extra-skeletal functions. The pathway determines circulating levels of 25-hydroxyvitamin D, the clinical biomarker of vitamin D status, and 1,25-dihydroxyvitamin D, the active hormone. Dysregulation contributes to chronic kidney disease progression, vitamin D toxicity, and altered mineral metabolism. Research into GO:0042359 informs nutritional guidelines, therapeutic dosing, and drug development targeting vitamin D metabolism.
• Vitamin D metabolic process controls calcium and phosphate homeostasis, essential for bone health.
• It determines the bioavailability of vitamin D from diet and supplements.
• It is dysregulated in chronic kidney disease, where renal 1-alpha-hydroxylation is impaired.
• Vitamin D toxicity arises from excessive intake and altered metabolism, leading to hypercalcemia.
• The pathway is a target for drugs modulating CYP24A1 and CYP27B1.
• Vitamin D-binding protein influences transport and tissue delivery of vitamin D metabolites.
• Gut microbiome may contribute to vitamin D2 synthesis, expanding the metabolic landscape.
• Genetic variants in CYP2R1 and VDR affect vitamin D status and disease risk.
• The process is conserved across vertebrates, enabling model organism studies.
• Understanding it aids in designing CRISPR models for causal gene validation.
What Happens During vitamin D metabolic process?
Absorption and transport of vitamin D
In simple terms: Vitamin D from food or skin enters the body and is carried by a binding protein.
Vitamin D2 and D3 are absorbed from the intestine or synthesized in the skin and then transported in the bloodstream bound to vitamin D-binding protein (DBP). Bioavailability depends on dietary fat and the efficiency of absorption, which varies among individuals. DBP delivers vitamin D metabolites to target tissues, including liver and kidney.
Hepatic 25-hydroxylation
In simple terms: The liver adds a hydroxyl group to vitamin D to make 25-hydroxyvitamin D.
In the liver, cytochrome P450 enzymes, primarily CYP2R1, catalyze the 25-hydroxylation of vitamin D2 and D3 to form 25-hydroxyvitamin D (calcidiol), the major circulating metabolite. This step is not tightly regulated and reflects vitamin D intake and synthesis. 25-hydroxyvitamin D is the clinical biomarker for vitamin D status.
Renal 1-alpha-hydroxylation
In simple terms: The kidney activates vitamin D by adding another hydroxyl group.
In the kidney, CYP27B1 (25-hydroxyvitamin D-1-alpha-hydroxylase) converts 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D (calcitriol), the biologically active hormone. This step is tightly regulated by parathyroid hormone, calcium, phosphate, and FGF23. Calcitriol binds the vitamin D receptor (VDR) to regulate gene expression.
Catabolism and inactivation
In simple terms: Enzymes break down active vitamin D to prevent excess.
CYP24A1 initiates the catabolism of 1,25-dihydroxyvitamin D and 25-hydroxyvitamin D by 24-hydroxylation, leading to inactivation and excretion. This feedback mechanism prevents vitamin D toxicity and maintains homeostasis. Other enzymes such as CYP3A4 also contribute to vitamin D catabolism.
Receptor-mediated signaling
In simple terms: Active vitamin D binds a receptor that turns genes on or off.
1,25-dihydroxyvitamin D binds VDR, a nuclear receptor that heterodimerizes with RXR and regulates transcription of target genes involved in calcium transport, bone remodeling, and immune function. This genomic action mediates most biological effects of vitamin D.
Key Genes Involved in GO:0042359 vitamin D metabolic process
The following genes encode enzymes, transporters, and receptors that execute and regulate vitamin D metabolic process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CYP2R1 | 25-hydroxylase in liver | Determines circulating 25-hydroxyvitamin D levels; target for knockout studies |
| CYP27B1 | 1-alpha-hydroxylase in kidney | Produces active 1,25-dihydroxyvitamin D; dysregulated in CKD |
| CYP24A1 | 24-hydroxylase; catabolism | Inactivates vitamin D; mutations cause hypercalcemia |
| VDR | Nuclear receptor for 1,25-dihydroxyvitamin D | Mediates genomic effects; knockout models show bone and immune phenotypes |
| GC | Vitamin D-binding protein | Transports vitamin D metabolites; influences bioavailability |
| CYP3A4 | Alternative catabolic enzyme | Contributes to vitamin D clearance |
| CYP2J2 | Vitamin D hydroxylase | Extrahepatic metabolism |
| CYP27A1 | 25-hydroxylase | Alternative activation pathway |
| LRP2 | Megalin; renal reabsorption | Uptake of DBP-bound vitamin D |
| CUBN | Cubilin; renal reabsorption | Cofactor for megalin-mediated uptake |
| FGF23 | Regulates phosphate and vitamin D | Inhibits CYP27B1 and induces CYP24A1 |
| PTH | Parathyroid hormone | Stimulates CYP27B1; regulates calcium |
| RXRA | Retinoid X receptor alpha | Heterodimer partner for VDR |
| CYP24A1 | Catabolic enzyme | Feedback regulation |
| SLC34A1 | Phosphate transporter | Indirectly linked to vitamin D metabolism |
| KL | Klotho | Cofactor for FGF23 signaling |
| CYP2R1 | Hepatic 25-hydroxylation | Genetic variants affect vitamin D status |
| VDR | Transcriptional regulation | Polymorphisms linked to disease risk |
How Is vitamin D metabolic process Regulated?
Vitamin D metabolic process is regulated by a feedback loop involving parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), calcium, and phosphate. PTH stimulates CYP27B1 expression and activity, increasing 1,25-dihydroxyvitamin D production, while FGF23 inhibits CYP27B1 and induces CYP24A1, reducing active vitamin D. 1,25-dihydroxyvitamin D itself suppresses PTH and CYP27B1 and induces CYP24A1, providing negative feedback. Vitamin D-binding protein levels and genetic variants in CYP2R1, CYP27B1, and VDR also modulate the pathway.
vitamin D metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CYP27B1 | Vitamin D-dependent rickets type 1A | Knockout mouse; point mutation knock-in |
| CYP24A1 | Idiopathic infantile hypercalcemia | Knockout and point mutation models |
| VDR | Vitamin D-resistant rickets | Knockout mouse; overexpression |
| GC | Vitamin D deficiency susceptibility | Knockout mouse |
| CYP2R1 | Altered vitamin D status | Knockout and knock-in models |
Chronic kidney disease
In chronic kidney disease, reduced renal mass and CYP27B1 activity lead to decreased 1,25-dihydroxyvitamin D production, contributing to mineral and bone disorders. FGF23 levels rise early and further suppress CYP27B1, exacerbating vitamin D deficiency. Therapies often include vitamin D analogs to compensate for impaired activation.
Vitamin D toxicity
Excessive intake or impaired catabolism can cause vitamin D toxicity, characterized by hypercalcemia and hyperphosphatemia. Pharmacokinetic studies show that high doses overwhelm the metabolic clearance capacity, leading to elevated 25-hydroxyvitamin D and active hormone. CYP24A1 mutations can predispose to toxicity.
Genetic disorders of vitamin D metabolism
Mutations in CYP27B1 cause vitamin D-dependent rickets type 1A, while CYP24A1 mutations cause idiopathic infantile hypercalcemia. These disorders highlight the importance of precise regulation of vitamin D activation and inactivation.
From vitamin D metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CYP2R1 affect circulating 25-hydroxyvitamin D? | CYP2R1 knockout cell line or mouse |
| How do CYP24A1 point mutations cause hypercalcemia? | Point mutation knock-in in HEK293 or osteoblast-like cells |
| Can VDR overexpression rescue vitamin D signaling? | VDR overexpression in VDR-null cells |
| What is the role of DBP in vitamin D transport? | GC knockout hepatocyte models |
| How does FGF23 regulate CYP27B1? | Knock-in of FGF23-responsive elements; reporter assays |
| Does gut microbiome synthesize vitamin D2? | Microbiome co-culture with intestinal cells |
How to Study the vitamin D metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | Vitamin D metabolite concentrations | Clinical and pharmacokinetic studies |
| CRISPR knockout screening | Gene essentiality for vitamin D response | Discovery of novel regulators |
| VDRE luciferase reporter | VDR transcriptional activity | Functional validation of VDR variants |
| RNA-seq | Transcriptional changes after vitamin D treatment | Target gene identification |
| ChIP-seq | VDR binding sites | Genome-wide VDR mapping |
| Immunoblotting | Protein expression of CYP enzymes | Validation of knockout/overexpression |
| Calcium flux assays | Calcium homeostasis | Functional impact of metabolic genes |
LC-MS/MS for vitamin D metabolites
Liquid chromatography-tandem mass spectrometry is the gold standard for quantifying vitamin D2, D3, 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D in biological samples. It enables pharmacokinetic studies and assessment of metabolic flux.
CRISPR screening for metabolic genes
Genome-wide CRISPR knockout screens can identify genes that modulate vitamin D sensitivity or metabolism in cell models. Hits can be validated by targeted knockout and metabolite profiling.
Reporter assays for VDR activity
Vitamin D response element (VDRE) luciferase reporters measure VDR transcriptional activity in response to 1,25-dihydroxyvitamin D. These assays are used to study mutations in VDR or metabolic enzymes.
Animal models for vitamin D metabolism
Knockout and transgenic mice for Cyp27b1, Cyp24a1, and Vdr have elucidated physiological roles of vitamin D metabolites. These models are essential for translational research.
How CRISPR Can Be Used to Study GO:0042359 vitamin D metabolic process
Knockout
CRISPR knockout of CYP2R1, CYP27B1, CYP24A1, or VDR in cell lines (e.g., HepG2, HEK293) ablates specific metabolic steps, enabling assignment of function. Knockout models show altered vitamin D metabolite profiles and downstream signaling.
Point Mutation
Point mutations mimicking human polymorphisms (e.g., CYP2R1 rs10741657) can be introduced to study effects on enzyme activity and vitamin D status. These models help establish causality of genetic variants.
Knock-in
Knock-in of tagged CYP27B1 or VDR (e.g., GFP, HA) allows visualization and immunoprecipitation of endogenous proteins. Knock-in of disease-associated mutations (e.g., CYP24A1) recapitulates hypercalcemia phenotypes.
Overexpression
Overexpression of VDR or CYP27B1 in vitamin D-responsive cells enhances signaling and can rescue deficiency phenotypes. Overexpression models are useful for gain-of-function studies.
How EDITGENE Supports vitamin D metabolic process Research
Researchers studying vitamin D metabolic process-related genes often need to determine whether a candidate gene is causally involved in metabolite production, receptor signaling, or disease phenotypes. EDITGENE provides CRISPR-based cell model services to enable such causal studies with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for vitamin D metabolic process research.
Frequently Asked Questions About vitamin D metabolic process
What is GO:0042359 vitamin D metabolic process?
GO:0042359 is a Gene Ontology biological process term describing the chemical reactions and pathways involving vitamin D, including calciferol (vitamin D2) and cholecalciferol (vitamin D3), which are fat-soluble compounds derived from delta-5,7 steroids and central to calcium metabolism.
What genes are involved in vitamin D metabolic process?
Key genes include CYP2R1, CYP27B1, CYP24A1, VDR, GC, CYP3A4, and CYP27A1, which encode enzymes and transport proteins for vitamin D activation, transport, and degradation.
How is vitamin D activated in the body?
Vitamin D is first 25-hydroxylated in the liver by CYP2R1, then 1-alpha-hydroxylated in the kidney by CYP27B1 to form active 1,25-dihydroxyvitamin D.
What is the role of vitamin D-binding protein?
Vitamin D-binding protein (GC) transports vitamin D metabolites in the bloodstream and delivers them to target tissues, influencing bioavailability.
How does vitamin D metabolic process relate to chronic kidney disease?
In chronic kidney disease, reduced CYP27B1 activity and elevated FGF23 impair vitamin D activation, contributing to mineral and bone disorders.
What causes vitamin D toxicity?
Vitamin D toxicity results from excessive intake or impaired catabolism, leading to hypercalcemia; pharmacokinetic studies show that high doses overwhelm metabolic clearance.
Can CRISPR be used to study vitamin D metabolism?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal studies of genes like CYP2R1, CYP27B1, CYP24A1, and VDR.
What are the symptoms of vitamin D deficiency?
Vitamin D deficiency can cause rickets in children and osteomalacia in adults, along with muscle weakness and increased fracture risk.
How is vitamin D status measured?
Serum 25-hydroxyvitamin D is the standard biomarker, typically measured by LC-MS/MS or immunoassay.
What is the difference between vitamin D2 and vitamin D3?
Vitamin D2 (ergocalciferol) is derived from plants and fungi, while vitamin D3 (cholecalciferol) is synthesized in skin or from animal sources; both are metabolized similarly but with differences in bioavailability and catabolism.
Conclusion
GO:0042359 vitamin D metabolic process is a fundamental biological pathway that governs the activation, transport, and degradation of vitamin D compounds, with far-reaching implications for calcium homeostasis, bone health, and chronic disease. Research using CRISPR models and advanced analytical methods continues to uncover genetic and regulatory mechanisms, offering opportunities for therapeutic intervention. Understanding this process is essential for interpreting vitamin D status and developing targeted therapies.
References
- 1. Delrue C et al.. 2023. Vitamin D and Vitamin D-Binding Protein in Health and Disease.. Int J Mol Sci 24(5) PMID: 36902073
- 2. Borel P et al.. 2015. Vitamin D bioavailability: state of the art.. Crit Rev Food Sci Nutr 55(9):1193-205 PMID: 24915331
- 3. Chau YY et al.. 2012. Vitamin D in chronic kidney disease.. Indian J Pediatr 79(8):1062-8 PMID: 22544696
- 4. Jones G. 2008. Pharmacokinetics of vitamin D toxicity.. Am J Clin Nutr 88(2):582S-586S PMID: 18689406
- 5. Fleet JC. 2025. Differences in the absorption and metabolism of vitamin D(2), vitamin D(3), and 25 hydroxyvitamin D.. J Steroid Biochem Mol Biol 249:106718 PMID: 40043817
- 6. Chaves AV et al.. 2024. Short communication: Metabolic synthesis of vitamin D(2) by the gut microbiome.. Comp Biochem Physiol A Mol Integr Physiol 295:111666 PMID: 38763476
- 7. Harrison HE. 1981. Vitamin D.. Prog Clin Biol Res 61:95-108 PMID: 7033977
- 8. DeLuca HF. 1976. Vitamin D endocrinology.. Ann Intern Med 85(3):367-77 PMID: 183579
